



March 20, 2017  
FOR 8:30 AM RELEASE  
CSE: TBP  
OTC: GRPOF

## ***Aphria Exercises Warrants for Gross Proceeds of \$1.3 Million to Further Fund Tetra's Clinical Trials***

**Ottawa, Ontario - (Marketwired – March 20, 2017)** – Tetra Bio-Pharma Inc. (“Tetra Bio” or “the Company”) (CSE: TBP and OTC: GRPOF) is pleased to announce that Aphria Inc. (TSX-V: APH and USOTCQB: APHQF) has exercised their 5,000,000 warrants for aggregate gross proceeds of \$1,300,000. The proceeds from the warrant exercise will be used to advance the clinical trials being developed in PhytoPain Pharma Inc., a subsidiary of Tetra.

"We would like to thank Aphria for their continued support and investment in the research and development being conducted by the science team at Tetra," said Andre Rancourt, CEO of Tetra Bio-Pharma Inc. "By exercising their warrants ahead of schedule, this further confirms Aphria's commitment to accelerate Tetra's development work. I am pleased to report to shareholders that Tetra is in a solid financial position with over \$4 million to continue advancing its strategic plan of becoming a leading bio-pharma organization focused on cannabis."

### **About Aphria:**

Aphria Inc., one of Canada's lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. We are the first public licensed producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters. For more information, visit [www.Aphria.com](http://www.Aphria.com).

### **About Tetra Bio Pharma:**

Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE: TBP) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: [www.tetrabiopharma.com](http://www.tetrabiopharma.com).

**For further information, please contact Tetra Bio-Pharma Inc.**

Dr. Guy Chamberland  
Chief Science Officer  
Phone: (514) 220-9225

André Rancourt  
Chief Executive Officer  
Phone: (613) 689-0714

*The Canadian Securities Exchange ("CSE") has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.*

**Forward-looking statements**

*Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.*